Welcome to our dedicated page for Becton Dickinson & Co SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Becton, Dickinson and Company filings document the reporting, governance and capital-structure matters of a New York Stock Exchange-listed medical technology issuer. Its Form 8-K disclosures cover quarterly operating results, non-GAAP financial measures, dividend and capital allocation updates, executive appointments, compensatory arrangements and amendments to corporate by-laws.
The filing record also documents BD's completed separation of its Biosciences and Diagnostic Solutions business and related recast historical financial information presenting that business as discontinued operations. Capital-structure disclosures include registered common stock, NYSE-listed notes and tender-offer activity involving senior notes and debentures.
Becton, Dickinson and Company director Robert Luther Huffines received 1,098 shares of common stock in the form of restricted stock units on January 27, 2026. The units were awarded at a price of $0 under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
Following this grant and units accumulated through dividend reinvestment since his last report, Huffines now beneficially owns 1,279 shares of Becton Dickinson common stock in direct form.
Becton, Dickinson and Company director Christopher Ian Montague Jones received 1,098 shares of common stock on January 27, 2026 as an equity award at a price of $0 per share. These shares were granted in the form of restricted stock units under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
Following this transaction, Jones beneficially owned 24,304 shares of Becton Dickinson common stock in direct form. The total includes units that were added through dividend reinvestment since his prior ownership report.
Becton Dickinson director Timothy M. Ring reported an equity award in the form of restricted stock units. On January 27, 2026, he acquired 1,098 shares of common stock at $0 under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
After this award, Ring beneficially owned 59,160 shares of Becton Dickinson common stock directly, plus 2,285 shares indirectly through a 401(k) plan, which includes units accumulated from dividend reinvestment since his prior report.
Becton, Dickinson and Company director Bertram L. Scott received 1,098 shares of common stock on January 27, 2026, at a price of $0 per share. The filing explains this represents restricted stock units awarded under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
After this grant, Scott beneficially owned 37,716 shares directly, which include units acquired through dividend investment since his last report.
Becton, Dickinson and Company director Joanne Waldstreicher received 1,098 shares of common stock in the form of restricted stock units on January 27, 2026. The units were granted at a price of $0 under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
Following this grant and units acquired through dividend reinvestment since her last report, Waldstreicher beneficially owns 3,391 shares of Becton Dickinson common stock in direct ownership. This filing reflects equity-based compensation rather than an open-market purchase.
Becton, Dickinson and Company director Jacqueline Wright reported an equity award of 1,098 shares of common stock on January 27, 2026. The award was granted at a price of $0 per share as restricted stock units under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
After this grant and including units acquired through dividend reinvestment since her last report, Wright beneficially owns 1,279 common shares in direct form. This filing reflects routine director compensation in the form of equity awards rather than an open-market purchase.
Becton, Dickinson and Company executive Michael Feld, EVP, CRO & President of Life Sciences, reported selling 75 shares of BDX common stock on January 26, 2026 at a price of $202.73 per share. Following this sale, he directly beneficially owns 16,431 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan that Feld adopted on February 7, 2025.
Becton, Dickinson and Company (BDX) insider files a Form 144 to sell a small block of shares under an existing trading plan. The notice covers a proposed sale of 75 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 01/26/2026. The filing states an aggregate market value of 15134.25 for these 75 shares, compared with 285418551 shares of common stock outstanding.
The securities to be sold were acquired as restricted stock units from the issuer on 08/20/2025, in an amount of 75 shares. The form also lists prior Rule 10b5-1 sales for Michael Feld over the past three months, including 74, 75, and 57 common shares sold on 12/26/2025, 12/01/2025, and 10/27/2025, respectively, with disclosed gross proceeds for each transaction.
Becton, Dickinson and Company senior vice president, controller and chief accounting officer Pamela L. Spikner reported a routine share withholding related to equity compensation. On January 21, 2026, 84 shares of common stock were withheld at a price of $0.00 per share to cover withholding taxes tied to the vesting of previously granted restricted stock units. After this tax-withholding transaction, Spikner directly beneficially owned 1,832 shares of Becton Dickinson common stock.
Becton Dickinson & Co executive Michael David Garrison reported multiple stock transactions. On 01/15/2026, he exercised 3,054 stock appreciation rights at an exercise price of $167.91 per share, receiving 3,054 shares of common stock. He then disposed of 2,454 shares at $209 per share and sold 600 additional shares at $209 and 1,010 shares at $206.54.
After these transactions, he directly owned 12,095 shares of Becton Dickinson common stock. The filing notes that the reported transactions were made under a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025.